期刊文献+

川崎病合并冠状动脉瘤患儿应用华法林治疗的安全性 被引量:4

Safety of warfarin therapy in children with coronary aneurysm due to Kawasaki disease
原文传递
导出
摘要 目的探讨川崎病合并冠状动脉瘤患儿应用华法林治疗的安全性和转归。方法选择2011至2020年湖南省人民医院收治的川崎病合并巨大冠状动脉瘤、1支冠状动脉血管内发生多个冠状动脉瘤或冠状动脉内发生血栓的患儿共21例进行前瞻性研究,应用华法林治疗,将国际标准化比值(INR)目标范围控制在2.0~3.0。在治疗开始时,治疗后1、2、3、4周及2、3、6、12个月,观察治疗前后冠状动脉瘤直径、数量、部位和冠状动脉内血栓的变化,并监测INR、心电图、肌酸激酶同工酶(CK-MB)、肌钙蛋白I。实施规范的华法林出血风险培训与管理,并根据家长实际落实情况,分为落实组和未落实组,比较2组患儿出血的发生情况。组间比较采用秩和检验或Fisher确切概率法。结果21例患儿男15例、女6例,发病年龄为2月龄至6岁。入组时评估冠状动脉病变为Ⅱ级有4例、Ⅲ级有7例、Ⅳ级有7例、Ⅴ级有3例。10例发生血栓的患儿临床发现血栓的时间为病程第4天至4个月。应用华法林治疗后,其剂量分布在0.06~0.10 mg/(kg·d),INR为1.80~2.59,10例有血栓的患儿有8例消失,2例未消失的Ⅴ级患儿的血栓有不同程度机化。治疗后,4例Ⅱ级病变患儿的冠状动脉均恢复正常;7例Ⅲ级病变患儿中有3例冠状动脉瘤消失,4例无改变;7例Ⅳ级病变患儿中5例冠状动脉瘤缩小为Ⅲ级,2例无改变;3例Ⅴ级病变患儿瘤体无改变。治疗后均没有新发血栓及新冠状动脉瘤出现。21例患儿治疗前后心电图无特殊改变,治疗前后肌钙蛋白I和CK-MB差异均无统计学意义[0.07(0~3.01)比0.04(0~0.29)μg/L,20.6(11.2~58.2)比29.0(16.7~47.0)U/L,Z=0.932、1.906,均P>0.05]。华法林出血风险管理落实组患儿出血发生率明显低于未落实组,差异有统计学意义(2/15比4/6,Fisher值=5.689,P=0.031)。结论应用INR 2.0~3.0为目标范围,结合川崎病并冠状动脉瘤的严重程度来调整华法林剂量,并予以规 Objective To investigate the safety of warfarin for Kawasaki disease(KD)with coronary artery aneurysm(CAA)and its prognosis.Methods Twenty one children with KD complicated with giant CAA,multiple CAA in one coronary artery or thrombosis in coronary artery were enrolled in this prospective study.Warfarin was used to control the goal international normalized ratio(INR)ranging from 2.0 to 3.0.The CAA diameter,number,location and thrombus in coronary artery were recorded at the beginning of treatment,1,2,3,4 weeks and 2,3,6,12 months after treatment,as well as the influence on INR,electrocaroliogram,creatine kinase-MB(CK-MB),troponin I.Standardized warfarin bleeding risk training and management was implemented.Children were divided into implementation group and non-implementation group according to the status of actual implementation of their parents.The incidence of bleeding events was compared between the two groups.Comparisons between groups were performed using a Rank sum test and a Fisher exact test.Results In the 21 patients(15 males and 6 females),the age of onset ranged from 2 months to 6 years.There were 4 cases with gradeⅡ,7 cases with gradeⅢ,7 cases with gradeⅣand 3 cases with gradeⅤaccording to the severity of coronary arterial lesions before treatment.The time of clinical detection of thrombus in 10 children with thrombosis ranged from the fourth day to the fourth month.The dose distribution of warfarin was 0.06-0.10 mg/(kg·d),and the INR was 1.80-2.59.Among the 10 cases with thrombus,8 cases had disappearance of thrombi and 2 cases with gradeⅤhad thrombus organization to different degree.After treatment,the coronary artery ectasia of the 4 cases with gradeⅡall returned to normal.Among the 7 cases with gradeⅢ,3 cases of coronary artery aneurysms returned to normal,and 4 cases did not change.Among the 7 cases with gradeⅣ,5 cases of coronary artery aneurysms shrank to gradeⅢ,and 2 cases remained unchanged.Three cases with gradeⅤlesions had no changes in aneurysm.Neither new thrombus no
作者 何学华 朱潜力 袁勇华 龙湘党 夏晓辉 王胜 胡灿 He Xuehua;Zhu Qianli;Yuan Yonghua;Long Xiangdang;Xia Xiaohui;Wang Sheng;Hu Can(Department of Children′s Cardiovascular Disease,Hunan Provincial People′s Hospital,Changsha 410005,China;Department of Ultrasoud,Hunan Provincial People′s Hospital,Changsha 410005,China;Department of Pediatrics,the First Affiliated Hospital of Shaoyang College,Shaoyang 422000,China)
出处 《中华儿科杂志》 CAS CSCD 北大核心 2021年第2期95-100,共6页 Chinese Journal of Pediatrics
关键词 粘膜皮肤淋巴结综合征 华法林 冠状动脉瘤 血栓形成 Mucocutaneous lymph node syndrome Warfarin Coronary aneurysm Thrombosis
  • 相关文献

参考文献5

二级参考文献42

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2刘晓琴,黄国英,梁雪村,陶子喻,陈伟达,林其珊.川崎病恢复期患儿血管病变的超声研究[J].中华医学杂志,2007,87(30):2117-2120. 被引量:3
  • 3Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652. 被引量:1
  • 4Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867. 被引量:1
  • 5Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868. 被引量:1
  • 6Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293. 被引量:1
  • 7Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719. 被引量:1
  • 8Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S. 被引量:1
  • 9Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S. 被引量:1
  • 10Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496. 被引量:1

共引文献759

同被引文献44

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部